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Abstract— Three nucleoside analogues, 3′–fluoro–2′,3′–dideoxythymidine (FLT), 3′–azido–2′,3′–dideoxythymidine (AZT), and 2',3'–
dideoxy–3'–thiacytidine (3TC) were conjugated with three different dicarboxylic acids to afford the long chain dicarboxylate esters of 
nucleosides. In general, dinucleoside ester conjugates of FLT and 3TC with long chain dicarboxylic acids exhibited higher anti–HIV 
activity than their parent nucleosides. Dodecanoate and tetradecanoate dinucleoside ester derivatives of FLT were found to be the most 
potent compounds with EC50 values of 0.8–1.0 nM and 3–4 nM against HIV–1US/92/727 and HIV–1IIIB cells, respectively. The anti–HIV 
activity of the 3TC conjugates containing long chain dicarboxylate diester (EC50 = 3–60 nM) was improved by 1.5–66 fold when 
compared to 3TC (EC50 = 90–200 nM). This study reveals that the symmetrical ester conjugation of dicarboxylic acids with a number of 
nucleosides results in conjugates with improved anti–HIV profile.  
Nucleoside reverse transcriptase inhibitors (NRTIs) 
are commonly used for the treatment of human 
immunodeficiency virus (HIV) infection. NRTIs exert 
their pharmacological effects after intracellular 
phosphorylation to monophosphates, diphosphates, and 
triphosphates in the presence of the host cellular kinases. 
Nucleoside triphosphates inhibit the reverse 
transcriptase, a crucial enzyme for HIV life cycle, 
through substrate competition with natural 
deoxynucleosides and incorporation into the viral DNA 
that leads to the chain termination.1,2 Some examples of 
commercially available NRTIs are 2',3'–dideoxy–3'–
thiacytidine (3TC), 2',3'–didehydro–2',3'–
dideoxythymidine (d4T), 2',3'–dideoxy–5–fluoro–3'–
thiacytidine (FTC), 2',3'–dideoxycytidine (ddC), 3'–
azido–3'–deoxythymidine (AZT), and (R)–9–(2–
phosphonomethoxypropyl)adenine (TFV). In spite of the 
potent anti–HIV activities, NRTIs face major challenges 
such as high levels of clinical toxicity including bone 
marrow suppression and neuropathy, drug resistance, 
low therapeutic index, and/or mitochondrial toxicity.3–6 
Combination therapy in Highly Active Antiretroviral 
Therapy (HAART) programs using different classes of 
anti–HIV drugs provides several potential advantages, 
such as reducing the drug resistance and controling 
HIV–1 infection.7  
Despite the success of HAART, the hydrophilic 
nature of NRTIs leads to limited cellular uptake and 
bioavailability. Various nucleoside prodrugs have been 
synthesized in the past to overcome these short 
comings.3,8 We have previously reported the synthesis of 
lipophilic fatty acyl esters of anti–HIV nucleosides; 
AZT, 3′–fluoro–2′,3′–dideoxythymidine (FLT), 3TC, 
and d4T.9–13 Lipophilic fatty acyl esters of anti–HIV 
nucleosides demonstrated higher anti–HIV activity 
compared to the parent nucleosides.10,14 Cellular uptake 
studies indicated that the long chain fatty acyl esters of 
3TC had improved cellular uptake due to improved 
lipophilicity and were able to hydrolyze to parent 
nucleoside intracellularly.14 
Herein, we report the synthesis of long chain 
dicarboxylic acid esters of FLT, AZT and 3TC to 
determine whether the presence of two nucleosides on 
fatty acyl chains will affect the overall anti–HIV 
activity. Three long dicarboxylic acids with chain 
lengths of C10 (sebacic acid), C12 (dodecandioic acid), 
and C14 (tetradecandioic acid) were selected for the 
conjugation. The conjugates were expected to have high 
lipophilic nature because of the presence of long chain 
dicarboxylate esters and thereby to have improved 
cellular uptake properties. We have previously shown 
the lipophilic nature and/or higher cellular uptake of the 
fatty acyl esters of the nucleosides compared to the their 
parent nucleosides.9,10,14 Furthermore, the conjugation of 
anti–HIV nucleosides with three long chain dicarboxylic 
acids will provide insights about the structure–activity 
relationships of these conjugates. Once the ester enters 
the cells, it is expected to release two parent nucleosides 
after intracellular ester hydrolysis as shown previously 
with fatty acyl ester conjugates of 3TC.14 The results of 
this study demonstrate that conjugation of two similar 
nucleosides with dicarboxylic fatty acids yields anti–
HIV agents having enhanced lipophilicity and increased 
potency. These conjugates were envisioned and 
designed to be used as topical anti-HIV microbicides, 
which are topically applied agents that prevent or reduce 
transmission of HIV/AIDS.  
Symmetrical long chain fatty acyl dicarboxylate 
esters of FLT–FLT, AZT–AZT, and 3TC–3TC were 
synthesized. Scheme 1 depicts the general synthesis of 
 dinucleoside dicarboxylate ester derivatives of FLT–
FLT (6–8) and AZT–AZT (9–11). The compounds were 
synthesized by reaction of commercially available 
nucleosides with three different dicarboxylic acids 
(sebacic acid, dodecandioic acid, and tetradecandioic 
acid) in the presence of 1,1,3,3–tetramethyluronium 
hexafluorophosphate (HBTU) as coupling reagent and 
N,N–diisopropylethylamine (DIPEA) as the base 
(Scheme 1) in DMF at room temperature. The final 
products were purified by using a reversed phase HPLC. 
  
Scheme 1. Synthesis of 5′,5′–dinucleoside dicarboxylate ester 
derivatives of FLT (6–8) and AZT (9–11). 
Scheme 2. Synthesis of symmetrical 5,5–dinucleoside 
dicarboxylate ester derivatives of 3TC (21–24). 
 
The Synthesis of fatty acyl dicarboxylate esters of 
3TC is shown in Scheme 2. N4–amino protection of 
3TC was required before conjugation with dicarboxylic 
acids. First, tert–butyldimethylsilyl chloride (TBDMS–
Cl) was reacted with 3TC in the presence of imidazole to 
afford 5–O–TBDMS–3TC. Then N4–amino group of 
5–O–TBDMS–3TC was further protected with 4,4′–
dimethoxytrityl (DMTr) protecting group by reaction 
with DMTr–Cl in the presence of pyridine. Finally, 
TBDMS was removed by using tetrabutylammonium 
fluoride (TBAF) to yield N4–DMTr–3TC according to 
the previously reported procedure by us.15 The 
esterification was carried out with four different 
dicarboxylic acids (e.g., succinic acid, sebacic acid, 
dodecandioic acid, and tetradecandioic acid) in the 
presence of HBTU and DIPEA to afford N4–DMTr 
protected dinucleoside dicarboxylate esters (17–20) as 
crude products that were isolated by using extraction. 
The DMTr group was deprotected by heating the 
reaction mixture in 80% acetic acid in water (v/v) at 80 
°C to give di–3TC–dicarboxylate esters (21–24) 
(Scheme 2).  
The chemical structures of the final products were 
characterized by nuclear magnetic resonance 
spectrometry (1H NMR and 13C NMR), and were 
confirmed by a high–resolution PE Biosystems Mariner 
API time–of–flight electrospray mass spectrometer. The 
purity of the final products (>95%) was confirmed by 
using a Hitachi analytical HPLC system on a C18 
column using a gradient system (water:acetonitrile 30:70 
v/v) at constant flow rate of 1 mL/min with UV 
detection at 265 nm. 
Synthesized dinucleoside ester conjugates were 
evaluated for their ability to inhibit HIV–1 (subtype B, 
US/92/727) and (subtype IIIB) replication in human 
PBMC and CEM–SS cells, respectively.16,17 Table 1 
illustrates the anti–HIV–1 activity (EC50) and 
cytotoxicity (TC50) of the synthesized compounds 
compared with their corresponding parent nucleosides. 
No cytotoxicity was observed up to the highest tested 
concentration (TC50  1000 nM) for the synthesized 
conjugates. 
The anti–HIV activity of the 3TC conjugates 
containing long chain dicarboxylate (22–24, EC50 = 3–
60 nM) was improved by 1.5–66 fold when compared to 
3TC (EC50 = 90–200 nM). The 3TC ester of 
tetradecandicarboxylic acid (24, EC50 = 3–30 nM) 
showed 3–66 times enhanced anti–HIV activity in 
comparison to 3TC. Dodecandicarboxylate ester of 3TC 
(23, EC50 = 9–20 nM) exhibited 4.5–22–fold higher 
anti–HIV activity than 3TC. The activity of decanoate 
ester of 3TC (22) was 1.5–6.6 times higher than 3TC. 
However, succinate ester of 3TC (7, EC50 = 130–150 
nM) had comparable anti–HIV activity with 3TC (EC50 
= 90–200 nM). These data indicate that the anti–HIV 
activity of dicarboxylate ester conjugates of 
dinucleosides depends on the chain length of the spacer 
between two nucleosides. The optimal antiviral activity 
for 3TC conjugates was obtained with dodecandioic and 
tetradecandioic ester conjugates. 
In general, dinucleoside ester conjugates of FLT (6–
8) and 3TC (22–24) with long chain dicarboxylic acids 
exhibited higher anti–HIV activity than their parent 
nucleosides. On the other hand, the AZT conjugates (9–
11, EC50 = 2–5 nM) showed comparable activity with 
AZT (EC50 = 2–8 nM) against HIV in both PBMC and 
CEM–SS assays. 
The dicarboxylic esters of FLT (6–8, EC50 = 0.76–1 
nM) exhibited slightly higher anti–HIV activity than 
their parent nucleoside FLT in PBMC assay against 
HIV–1US/92/727. Among all the conjugates, FLT esters 7 
and 8 were the most potent conjugates against HIV in 
the series with EC50 values of 0.97 and 0.76 nM, 
respectively, that was approximately 2 times higher than 
that of FLT (EC50 = 2 nM). The anti–HIV activity of 
FLT conjugates (6–8, EC50 = 3–4 nM) in CEM–SS’s 
against HIV–1III–B was found to be 5–6.6 times higher  
  
Table 1. Anti-HIV activity of dicarboxylic acid esters of dinucleoside conjugates.  
Compd Chemical Name 
PBMC/HIV-1US/92/727 CEM-SS/HIV-1IIIB 
Log P 
(Calcd)d 
EC50 
(nM)a 
TC50 
(nM)b 
TIc EC50 (nM)
a 
TC50 
(nM)b 
TIc 
 
         
1 (FLT) 3'-fluoro-2',3'-deoxythymidine 2.0 >500 >250 20.0 >500 >25 –0.41 
2 (AZT) 3'-azido-2',3'-dideoxythymidine 8.0 >1000 >125 2.0 >500 >250 ND
e 
12 (3TC) (-)-2',3'-dideoxy-3'-thiacytidine 90.0 >500 >5.6 200.0 >500 >2.5 0.06 
6  1,10-di-FLT-decanoate 1.0 >1000 >1000 4.0 >1000 >250 2.12 
7 1,12-di-FLT-dodecanoate 0.97 >1000 >1031 4.0 >1000 >250 2.96 
8 1,14-di-FLT-tetradecanoate 0.76 >1000 >1316 3.0 >1000 >333 3.79 
9 1,10-di-AZT-decanoate 4.0 >1000 >250 5.0 >1000 >200 ND 
10 1,12-di- AZT-dodecanoate 2.0 >1000 >500 4.0 >1000 >250 ND 
11 1,14-di-AZT-tetradecanoate 3.0 >1000 >333 3.0 >1000 >333 ND 
21 1,4-di-3TC-succinate 150.0 >1000 >7 130.0 >1000 >7.7 0.56 
22 1,10-di-3TC-decanoate 60.0 >1000 >17 30.0 >1000 >33 3.06 
23 1,12-di-3TC-dodecanoate 20.0 >1000 >50 9.0 >1000 >333 3.90 
24 1,14-di-3TC-tetradecanoate 30.0 >1000 >33 3.0 >1000 >333 4.73 
aEC50 (50% effective concentration), All the assays were carried out in triplicate (n = 3); 
bTC50 (50% toxic concentration), All the assays were carried out in 
triplicate (n = 3); cTherapeutic index (TC50/EC50); 
dCalculated partition coefficient using ChemBioDraw Ultra 12.0; eNot determined.
than FLT (EC50 = 20 nM). The attachment of the long 
chain dicarboxylic acid analogues to 1 and 12 enhanced 
their lipophilicity as shown by calculated partition 
coefficients (Log P) (Table 1). There was a correlation 
between lipophilicity and anti–HIV activity of the 
compounds since more lipophilic compounds exhibited 
higher anti–HIV activity compared to polar parent 
nucleoside analogues. As shown previously with other 
fatty acyl derivatives of nucleosides,14 the highly 
lipophilic conjugates could have higher cellular uptake 
that contributed to their improved anti–HIV activity. 
The anti–HIV activity of 1 (FLT, EC50 = 2 nM) in 
PBMC’s against HIV–1US/92/727 was found to be 4 and 
45 times higher than 2 (AZT, EC50 = 8 nM) and 12 
(3TC, EC50 = 45 nM), respectively. Similarly, the FLT 
esters of long chain dicarboxylic acids (6–8, EC50 = 
0.76–1.0 nM) were more potent than the corresponding 
AZT conjugates (9–11, EC50 = 2.0–4.0 nM) and 3TC 
conjugates (22–24, EC50 = 20–60 nM). 
A number of symmetrical 5′–O–substituted 
dicarboxylate ester derivatives of NRTIs were 
synthesized, and their anti–HIV activity was evaluated. 
In general, the conjugation of selected long chain 
dicarboxylic acids NRTIs resulted in better anti–HIV 
profiles than the corresponding parent nucleosides. 
Among all the dinucleoside diester derivatives, 
FLT–FLT conjugates 7 and 8 were found to have better 
anti–HIV activity than 1 and the other dicarboxylate 
dinucleoside derivatives. The data indicate that 
conjugation of the NRTIs with dicarboxylic acids is an 
effective strategy in achieving higher anti–HIV activity 
possibly by improving the lipophilicity and potentially 
cellular uptake of the parent nucleosides. These data 
provide the basis for rational optimization of NRTIs 
through conjugation of two nucleosides with long chain 
dicarboxylic acids.  
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